Overview

Phase II Randomised Trial of Induction Gemcitabine and Cisplatin Versus Gemcitabine, Cisplatin, Pembrolizumab and Bevacizumab (GPPB) in Nasopharyngeal Cancer

Status:
Not yet recruiting

Trial end date:
2026-03-28

Target enrollment:

Participant gender:

Summary

The investigators hypothesize that the addition of bevacizumab and pembrolizumab to induction cisplatin and gemcitabine is tolerable and improves metabolic complete response (mCR), relapse free survival (RFS) and overall survival (OS) compared to induction cisplatin and gemcitabine in patients with locally advanced nasopharyngeal cancer (NPC)

Phase:

Phase 2

Details

Lead Sponsor:

National University Hospital, Singapore

Treatments:

Bevacizumab
Cisplatin
Gemcitabine
Pembrolizumab